| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aggression | 109 | 2023 | 320 | 30.480 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 80 | 2023 | 276 | 27.810 |
Why?
|
| Personality Disorders | 52 | 2022 | 146 | 13.760 |
Why?
|
| Impulsive Behavior | 52 | 2023 | 281 | 11.690 |
Why?
|
| Anger | 25 | 2023 | 78 | 6.140 |
Why?
|
| Emotions | 23 | 2022 | 341 | 4.950 |
Why?
|
| Serotonin | 18 | 2015 | 218 | 4.130 |
Why?
|
| Adult | 134 | 2023 | 25656 | 3.890 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 30 | 2021 | 216 | 3.810 |
Why?
|
| Psychiatric Status Rating Scales | 35 | 2019 | 487 | 2.930 |
Why?
|
| Emotional Intelligence | 6 | 2017 | 22 | 2.860 |
Why?
|
| Male | 131 | 2022 | 40983 | 2.770 |
Why?
|
| Young Adult | 51 | 2020 | 5980 | 2.680 |
Why?
|
| Social Perception | 9 | 2022 | 95 | 2.500 |
Why?
|
| Personality | 6 | 2022 | 134 | 2.490 |
Why?
|
| Female | 122 | 2022 | 44546 | 2.490 |
Why?
|
| Psychometrics | 13 | 2022 | 327 | 2.470 |
Why?
|
| Humans | 166 | 2023 | 86656 | 2.460 |
Why?
|
| Self-Injurious Behavior | 10 | 2019 | 105 | 2.400 |
Why?
|
| Hostility | 7 | 2021 | 24 | 2.270 |
Why?
|
| Borderline Personality Disorder | 10 | 2020 | 33 | 2.090 |
Why?
|
| Amygdala | 5 | 2021 | 84 | 2.060 |
Why?
|
| Surveys and Questionnaires | 17 | 2023 | 2504 | 1.960 |
Why?
|
| Stress Disorders, Post-Traumatic | 5 | 2022 | 96 | 1.960 |
Why?
|
| Middle Aged | 65 | 2020 | 25035 | 1.950 |
Why?
|
| Inflammation | 7 | 2023 | 923 | 1.630 |
Why?
|
| Fluoxetine | 4 | 2015 | 42 | 1.580 |
Why?
|
| Suicide, Attempted | 7 | 2018 | 129 | 1.580 |
Why?
|
| Comorbidity | 19 | 2020 | 944 | 1.570 |
Why?
|
| Antisocial Personality Disorder | 6 | 2022 | 91 | 1.540 |
Why?
|
| Substance-Related Disorders | 4 | 2019 | 394 | 1.450 |
Why?
|
| Feeding and Eating Disorders | 3 | 2019 | 173 | 1.440 |
Why?
|
| C-Reactive Protein | 7 | 2023 | 190 | 1.410 |
Why?
|
| Brain Concussion | 2 | 2022 | 59 | 1.390 |
Why?
|
| Social Behavior | 6 | 2018 | 294 | 1.350 |
Why?
|
| Adolescent | 30 | 2023 | 8984 | 1.330 |
Why?
|
| Endocannabinoids | 2 | 2019 | 27 | 1.320 |
Why?
|
| Depressive Disorder, Major | 4 | 2019 | 158 | 1.310 |
Why?
|
| Frontal Lobe | 4 | 2017 | 130 | 1.280 |
Why?
|
| Growth Hormone | 3 | 2015 | 97 | 1.280 |
Why?
|
| Kynurenine | 2 | 2019 | 20 | 1.260 |
Why?
|
| Affect | 4 | 2018 | 386 | 1.220 |
Why?
|
| Affective Symptoms | 3 | 2018 | 47 | 1.210 |
Why?
|
| Interleukin-6 | 6 | 2023 | 256 | 1.180 |
Why?
|
| Homovanillic Acid | 4 | 2012 | 35 | 1.140 |
Why?
|
| Anxiety Disorders | 6 | 2023 | 148 | 1.140 |
Why?
|
| Personality Inventory | 9 | 2015 | 108 | 1.140 |
Why?
|
| Hydrocortisone | 3 | 2023 | 298 | 1.130 |
Why?
|
| Violence | 3 | 2021 | 143 | 1.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 1375 | 1.090 |
Why?
|
| Facial Recognition | 2 | 2016 | 15 | 1.080 |
Why?
|
| Prefrontal Cortex | 4 | 2020 | 130 | 1.040 |
Why?
|
| Mood Disorders | 2 | 2018 | 81 | 1.040 |
Why?
|
| Severity of Illness Index | 10 | 2020 | 1802 | 0.980 |
Why?
|
| Facial Expression | 3 | 2010 | 51 | 0.970 |
Why?
|
| Tryptophan | 3 | 2016 | 90 | 0.970 |
Why?
|
| Child Abuse | 4 | 2020 | 78 | 0.970 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2022 | 3361 | 0.960 |
Why?
|
| Statistics as Topic | 7 | 2015 | 238 | 0.940 |
Why?
|
| Interpersonal Relations | 4 | 2016 | 170 | 0.940 |
Why?
|
| Clonidine | 2 | 2015 | 37 | 0.920 |
Why?
|
| Suicidal Ideation | 5 | 2016 | 67 | 0.900 |
Why?
|
| Paroxetine | 4 | 2011 | 26 | 0.880 |
Why?
|
| Parental Death | 1 | 2022 | 1 | 0.870 |
Why?
|
| Parent-Child Relations | 3 | 2015 | 77 | 0.870 |
Why?
|
| Limbic System | 4 | 2012 | 23 | 0.860 |
Why?
|
| Oxidative Stress | 3 | 2020 | 448 | 0.850 |
Why?
|
| Hydroxyindoleacetic Acid | 3 | 2012 | 27 | 0.840 |
Why?
|
| Spinal Puncture | 8 | 2015 | 38 | 0.840 |
Why?
|
| Testosterone | 3 | 2017 | 271 | 0.840 |
Why?
|
| Verbal Behavior | 2 | 2014 | 32 | 0.820 |
Why?
|
| Personality Assessment | 7 | 2014 | 98 | 0.820 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2023 | 683 | 0.790 |
Why?
|
| Cognition | 5 | 2022 | 571 | 0.780 |
Why?
|
| Analysis of Variance | 11 | 2016 | 911 | 0.780 |
Why?
|
| Brain | 8 | 2016 | 2216 | 0.780 |
Why?
|
| Awareness | 2 | 2018 | 93 | 0.770 |
Why?
|
| Caffeine | 1 | 2021 | 81 | 0.770 |
Why?
|
| Self-Assessment | 2 | 2011 | 47 | 0.760 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2021 | 196 | 0.760 |
Why?
|
| Suicide | 2 | 2016 | 139 | 0.760 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 2 | 2011 | 45 | 0.750 |
Why?
|
| Twins | 3 | 2017 | 65 | 0.740 |
Why?
|
| Case-Control Studies | 10 | 2016 | 1807 | 0.720 |
Why?
|
| Receptors, Cannabinoid | 1 | 2019 | 4 | 0.720 |
Why?
|
| Brain Mapping | 9 | 2021 | 549 | 0.690 |
Why?
|
| Benzazepines | 1 | 2019 | 89 | 0.680 |
Why?
|
| Alcoholism | 2 | 2020 | 172 | 0.670 |
Why?
|
| Neurotransmitter Agents | 3 | 2013 | 106 | 0.670 |
Why?
|
| Sex Factors | 8 | 2021 | 1054 | 0.670 |
Why?
|
| Social Desirability | 1 | 2018 | 12 | 0.670 |
Why?
|
| Bipolar Disorder | 3 | 2019 | 377 | 0.660 |
Why?
|
| Deception | 1 | 2018 | 20 | 0.660 |
Why?
|
| Valproic Acid | 3 | 2015 | 24 | 0.660 |
Why?
|
| Adult Survivors of Child Abuse | 2 | 2015 | 10 | 0.650 |
Why?
|
| Depressive Disorder | 1 | 2019 | 218 | 0.640 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 3 | 2012 | 183 | 0.640 |
Why?
|
| Reproducibility of Results | 10 | 2023 | 2706 | 0.640 |
Why?
|
| Deoxyguanosine | 2 | 2015 | 28 | 0.620 |
Why?
|
| Gray Matter | 1 | 2017 | 33 | 0.610 |
Why?
|
| Health Status | 3 | 2010 | 360 | 0.610 |
Why?
|
| Neuropsychological Tests | 7 | 2016 | 502 | 0.610 |
Why?
|
| Biomarkers | 8 | 2016 | 1718 | 0.590 |
Why?
|
| Pilot Projects | 6 | 2022 | 840 | 0.590 |
Why?
|
| Cross-Sectional Studies | 6 | 2023 | 1621 | 0.580 |
Why?
|
| Perforant Pathway | 1 | 2016 | 6 | 0.570 |
Why?
|
| Defense Mechanisms | 1 | 2016 | 7 | 0.560 |
Why?
|
| Prevalence | 8 | 2020 | 1239 | 0.550 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2015 | 6 | 0.550 |
Why?
|
| Overweight | 1 | 2017 | 118 | 0.550 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 2006 | 44 | 0.550 |
Why?
|
| Oxytocin | 2 | 2009 | 71 | 0.550 |
Why?
|
| Stress, Psychological | 3 | 2020 | 313 | 0.540 |
Why?
|
| Models, Psychological | 3 | 2015 | 157 | 0.530 |
Why?
|
| Citalopram | 1 | 2015 | 20 | 0.530 |
Why?
|
| Toxoplasmosis | 1 | 2016 | 64 | 0.520 |
Why?
|
| Receptors, Interleukin-1 Type II | 1 | 2015 | 3 | 0.520 |
Why?
|
| White Matter | 1 | 2016 | 80 | 0.520 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 568 | 0.520 |
Why?
|
| Self-Control | 1 | 2015 | 10 | 0.510 |
Why?
|
| Self Report | 5 | 2021 | 288 | 0.510 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 75 | 0.500 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 155 | 0.500 |
Why?
|
| Object Attachment | 1 | 2014 | 20 | 0.490 |
Why?
|
| Aged | 15 | 2019 | 18421 | 0.490 |
Why?
|
| Dinoprost | 1 | 2014 | 26 | 0.490 |
Why?
|
| Blood Platelets | 2 | 2011 | 149 | 0.480 |
Why?
|
| Pituitary-Adrenal System | 2 | 2023 | 64 | 0.470 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2016 | 332 | 0.470 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2023 | 81 | 0.470 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 481 | 0.470 |
Why?
|
| Wounds and Injuries | 2 | 2015 | 231 | 0.460 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2013 | 46 | 0.450 |
Why?
|
| Child Behavior Disorders | 1 | 2013 | 76 | 0.450 |
Why?
|
| DNA Methylation | 1 | 2018 | 628 | 0.450 |
Why?
|
| Fluorobenzenes | 1 | 2012 | 33 | 0.440 |
Why?
|
| Glutamic Acid | 1 | 2013 | 152 | 0.440 |
Why?
|
| Neuropeptide Y | 1 | 2012 | 31 | 0.440 |
Why?
|
| Sulfides | 1 | 2012 | 68 | 0.440 |
Why?
|
| Aniline Compounds | 1 | 2012 | 55 | 0.440 |
Why?
|
| Internal-External Control | 2 | 2009 | 44 | 0.430 |
Why?
|
| Mental Processes | 1 | 2012 | 32 | 0.430 |
Why?
|
| Hyperkinesis | 1 | 2012 | 15 | 0.430 |
Why?
|
| Substance P | 1 | 2012 | 61 | 0.420 |
Why?
|
| Radioligand Assay | 1 | 2011 | 32 | 0.410 |
Why?
|
| Receptors, Serotonin, 5-HT2 | 1 | 2011 | 15 | 0.410 |
Why?
|
| Neurotic Disorders | 1 | 2011 | 13 | 0.410 |
Why?
|
| Hippocampus | 1 | 2015 | 442 | 0.410 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2011 | 83 | 0.410 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 180 | 0.410 |
Why?
|
| Harm Reduction | 1 | 2011 | 16 | 0.410 |
Why?
|
| Quality of Life | 2 | 2018 | 1585 | 0.410 |
Why?
|
| Reaction Time | 5 | 2012 | 309 | 0.410 |
Why?
|
| Psychological Tests | 4 | 2017 | 91 | 0.400 |
Why?
|
| Double-Blind Method | 7 | 2015 | 1824 | 0.400 |
Why?
|
| Diseases in Twins | 1 | 2011 | 65 | 0.400 |
Why?
|
| Piperidines | 1 | 2012 | 181 | 0.390 |
Why?
|
| Linear Models | 4 | 2016 | 422 | 0.390 |
Why?
|
| GABA-B Receptor Agonists | 1 | 2010 | 5 | 0.390 |
Why?
|
| Depression | 4 | 2019 | 473 | 0.390 |
Why?
|
| Receptors, GABA-B | 1 | 2010 | 7 | 0.390 |
Why?
|
| Baclofen | 1 | 2010 | 15 | 0.390 |
Why?
|
| Synapses | 1 | 2012 | 265 | 0.370 |
Why?
|
| Serotonin 5-HT1 Receptor Agonists | 1 | 2010 | 4 | 0.370 |
Why?
|
| Cerebral Cortex | 2 | 2012 | 584 | 0.370 |
Why?
|
| Nervous System | 1 | 2011 | 86 | 0.370 |
Why?
|
| Family Health | 1 | 2010 | 162 | 0.360 |
Why?
|
| Bariatric Surgery | 1 | 2012 | 194 | 0.360 |
Why?
|
| Pyrimidines | 2 | 2010 | 370 | 0.350 |
Why?
|
| Obesity, Morbid | 1 | 2012 | 225 | 0.350 |
Why?
|
| Synaptic Transmission | 1 | 2011 | 222 | 0.350 |
Why?
|
| Cohort Studies | 6 | 2019 | 2768 | 0.350 |
Why?
|
| Interview, Psychological | 2 | 2012 | 69 | 0.340 |
Why?
|
| Smoking | 2 | 2011 | 609 | 0.340 |
Why?
|
| Analgesics | 1 | 2010 | 119 | 0.340 |
Why?
|
| Amino Acids, Neutral | 1 | 2008 | 3 | 0.340 |
Why?
|
| Spouse Abuse | 1 | 2008 | 13 | 0.330 |
Why?
|
| Cues | 2 | 2012 | 175 | 0.330 |
Why?
|
| Glycerides | 2 | 2019 | 17 | 0.330 |
Why?
|
| Arachidonic Acids | 2 | 2019 | 39 | 0.330 |
Why?
|
| Alcoholic Intoxication | 1 | 2009 | 31 | 0.330 |
Why?
|
| Aging | 1 | 2013 | 691 | 0.330 |
Why?
|
| Psychotherapy, Group | 1 | 2008 | 33 | 0.330 |
Why?
|
| Arousal | 1 | 2009 | 170 | 0.320 |
Why?
|
| Self Concept | 5 | 2012 | 133 | 0.320 |
Why?
|
| Picolinic Acids | 2 | 2019 | 5 | 0.320 |
Why?
|
| Fenfluramine | 2 | 2010 | 20 | 0.320 |
Why?
|
| Norepinephrine | 2 | 2011 | 167 | 0.320 |
Why?
|
| Universities | 2 | 2021 | 135 | 0.320 |
Why?
|
| Anxiety | 4 | 2023 | 287 | 0.310 |
Why?
|
| United States | 7 | 2020 | 6681 | 0.300 |
Why?
|
| Exploratory Behavior | 1 | 2007 | 44 | 0.300 |
Why?
|
| Self Care | 2 | 2020 | 164 | 0.300 |
Why?
|
| Twin Studies as Topic | 1 | 2006 | 19 | 0.290 |
Why?
|
| Child | 9 | 2020 | 6928 | 0.290 |
Why?
|
| Brain Injuries | 1 | 2009 | 161 | 0.290 |
Why?
|
| Parents | 2 | 2023 | 272 | 0.280 |
Why?
|
| Ethanol | 1 | 2009 | 249 | 0.280 |
Why?
|
| Psychiatric Department, Hospital | 1 | 2005 | 4 | 0.270 |
Why?
|
| Schizotypal Personality Disorder | 1 | 2005 | 6 | 0.260 |
Why?
|
| Electroshock | 3 | 2009 | 17 | 0.260 |
Why?
|
| Mental Disorders | 4 | 2016 | 371 | 0.260 |
Why?
|
| Serotonin Receptor Agonists | 2 | 2019 | 15 | 0.250 |
Why?
|
| Visual Perception | 1 | 2008 | 319 | 0.250 |
Why?
|
| Ambulatory Care | 1 | 2005 | 181 | 0.240 |
Why?
|
| Pennsylvania | 3 | 2016 | 75 | 0.240 |
Why?
|
| Temporal Lobe | 1 | 2005 | 173 | 0.240 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 2003 | 18 | 0.240 |
Why?
|
| Administration, Oral | 3 | 2010 | 684 | 0.230 |
Why?
|
| Neural Pathways | 3 | 2011 | 308 | 0.220 |
Why?
|
| Interleukin-8 | 1 | 2023 | 86 | 0.220 |
Why?
|
| Happiness | 2 | 2016 | 12 | 0.220 |
Why?
|
| Risk Factors | 5 | 2015 | 5420 | 0.220 |
Why?
|
| Neuroticism | 1 | 2022 | 5 | 0.220 |
Why?
|
| Intelligence Tests | 2 | 2014 | 38 | 0.220 |
Why?
|
| Firearms | 1 | 2023 | 49 | 0.220 |
Why?
|
| Psychopathology | 1 | 2022 | 29 | 0.210 |
Why?
|
| Research Subjects | 1 | 2023 | 73 | 0.210 |
Why?
|
| Logistic Models | 3 | 2010 | 1188 | 0.210 |
Why?
|
| Psychophysiologic Disorders | 1 | 2021 | 7 | 0.210 |
Why?
|
| Crime | 2 | 2006 | 36 | 0.210 |
Why?
|
| Psychotherapy | 1 | 2022 | 74 | 0.210 |
Why?
|
| Radionuclide Imaging | 2 | 2012 | 220 | 0.210 |
Why?
|
| Attention | 3 | 2017 | 388 | 0.200 |
Why?
|
| Socioeconomic Factors | 3 | 2019 | 567 | 0.200 |
Why?
|
| Behavior Therapy | 1 | 2022 | 75 | 0.200 |
Why?
|
| Phobic Disorders | 2 | 2012 | 13 | 0.200 |
Why?
|
| Photic Stimulation | 2 | 2016 | 494 | 0.200 |
Why?
|
| Dopamine | 2 | 2015 | 275 | 0.200 |
Why?
|
| Age Factors | 4 | 2019 | 1851 | 0.200 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2012 | 238 | 0.200 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 819 | 0.190 |
Why?
|
| Behavior Control | 1 | 2020 | 4 | 0.190 |
Why?
|
| Twins, Dizygotic | 3 | 2012 | 40 | 0.190 |
Why?
|
| Twins, Monozygotic | 3 | 2012 | 57 | 0.190 |
Why?
|
| Time Factors | 5 | 2010 | 5211 | 0.190 |
Why?
|
| Follow-Up Studies | 4 | 2012 | 3642 | 0.190 |
Why?
|
| Parenting | 2 | 2015 | 67 | 0.190 |
Why?
|
| Chi-Square Distribution | 3 | 2010 | 364 | 0.190 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 143 | 0.180 |
Why?
|
| Nicotine | 1 | 2021 | 194 | 0.180 |
Why?
|
| Hope | 1 | 2019 | 4 | 0.180 |
Why?
|
| Social Class | 1 | 2020 | 128 | 0.180 |
Why?
|
| Classification | 1 | 2019 | 54 | 0.170 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1673 | 0.160 |
Why?
|
| Polyunsaturated Alkamides | 1 | 2018 | 6 | 0.160 |
Why?
|
| Work | 1 | 2018 | 16 | 0.160 |
Why?
|
| Anisotropy | 2 | 2016 | 62 | 0.160 |
Why?
|
| Observer Variation | 3 | 2005 | 603 | 0.160 |
Why?
|
| NF-kappa B | 1 | 2021 | 445 | 0.160 |
Why?
|
| Reference Values | 3 | 2005 | 674 | 0.160 |
Why?
|
| Health Surveys | 2 | 2017 | 239 | 0.150 |
Why?
|
| Bias | 3 | 2012 | 127 | 0.150 |
Why?
|
| Age of Onset | 4 | 2006 | 310 | 0.150 |
Why?
|
| Sex Characteristics | 2 | 2012 | 319 | 0.150 |
Why?
|
| Pain Measurement | 2 | 2009 | 321 | 0.150 |
Why?
|
| Statistics, Nonparametric | 2 | 2016 | 308 | 0.150 |
Why?
|
| Data Collection | 2 | 2012 | 372 | 0.150 |
Why?
|
| Gene Expression | 1 | 2021 | 1284 | 0.150 |
Why?
|
| Epigenomics | 1 | 2018 | 100 | 0.150 |
Why?
|
| Recurrence | 1 | 2020 | 1139 | 0.150 |
Why?
|
| Motion Pictures | 1 | 2016 | 11 | 0.150 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 204 | 0.150 |
Why?
|
| Ecological Momentary Assessment | 1 | 2017 | 25 | 0.150 |
Why?
|
| Kynurenic Acid | 1 | 2016 | 7 | 0.140 |
Why?
|
| Quinolinic Acid | 1 | 2016 | 9 | 0.140 |
Why?
|
| Sublimation, Psychological | 1 | 2016 | 2 | 0.140 |
Why?
|
| Intelligence | 2 | 2009 | 71 | 0.140 |
Why?
|
| Weight Gain | 1 | 2017 | 123 | 0.140 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2016 | 67 | 0.140 |
Why?
|
| Irritable Mood | 1 | 2015 | 10 | 0.140 |
Why?
|
| Risk | 1 | 2017 | 674 | 0.130 |
Why?
|
| Serotonin Agents | 1 | 2015 | 12 | 0.130 |
Why?
|
| Students | 1 | 2016 | 147 | 0.130 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 296 | 0.130 |
Why?
|
| Life Change Events | 2 | 2005 | 48 | 0.130 |
Why?
|
| Interleukins | 1 | 2015 | 134 | 0.130 |
Why?
|
| Decision Making | 2 | 2011 | 642 | 0.130 |
Why?
|
| Organ Size | 1 | 2015 | 363 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 456 | 0.120 |
Why?
|
| Sertraline | 1 | 2012 | 7 | 0.110 |
Why?
|
| Personality Tests | 1 | 2012 | 21 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 1204 | 0.110 |
Why?
|
| Period Circadian Proteins | 1 | 2012 | 10 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2011 | 7998 | 0.110 |
Why?
|
| Adenosine Deaminase | 1 | 2012 | 20 | 0.110 |
Why?
|
| Loneliness | 1 | 2012 | 24 | 0.110 |
Why?
|
| Psychology | 1 | 2012 | 24 | 0.110 |
Why?
|
| Biogenic Monoamines | 1 | 2012 | 8 | 0.110 |
Why?
|
| Body Temperature | 2 | 2010 | 124 | 0.110 |
Why?
|
| Radioimmunoassay | 1 | 2012 | 155 | 0.110 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2013 | 315 | 0.110 |
Why?
|
| Behavioral Research | 1 | 2011 | 10 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 579 | 0.100 |
Why?
|
| Tritium | 1 | 2011 | 133 | 0.100 |
Why?
|
| Avoidance Learning | 1 | 2011 | 16 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2018 | 4214 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 508 | 0.100 |
Why?
|
| Crime Victims | 1 | 2012 | 34 | 0.100 |
Why?
|
| Lysergic Acid Diethylamide | 1 | 2011 | 22 | 0.100 |
Why?
|
| Amino Acids | 1 | 2012 | 252 | 0.100 |
Why?
|
| Sleep Deprivation | 1 | 2012 | 137 | 0.100 |
Why?
|
| Receptor, Serotonin, 5-HT2B | 1 | 2010 | 2 | 0.100 |
Why?
|
| Iodine Radioisotopes | 1 | 2011 | 134 | 0.100 |
Why?
|
| Receptors, Neurotransmitter | 1 | 2011 | 25 | 0.100 |
Why?
|
| Cytokines | 1 | 2015 | 778 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 297 | 0.100 |
Why?
|
| Neuropeptides | 1 | 2011 | 112 | 0.090 |
Why?
|
| Synaptic Membranes | 1 | 2010 | 14 | 0.090 |
Why?
|
| Behavioral Symptoms | 1 | 2010 | 15 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2011 | 171 | 0.090 |
Why?
|
| Obesity | 1 | 2017 | 964 | 0.090 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 242 | 0.090 |
Why?
|
| Games, Experimental | 1 | 2009 | 10 | 0.090 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1621 | 0.090 |
Why?
|
| Chicago | 1 | 2014 | 1380 | 0.090 |
Why?
|
| Dominance-Subordination | 1 | 2009 | 8 | 0.090 |
Why?
|
| Empathy | 1 | 2011 | 147 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 916 | 0.090 |
Why?
|
| Social Adjustment | 1 | 2009 | 46 | 0.090 |
Why?
|
| Heart Rate | 1 | 2012 | 492 | 0.090 |
Why?
|
| Dendrites | 1 | 2010 | 99 | 0.090 |
Why?
|
| Competitive Behavior | 1 | 2009 | 28 | 0.090 |
Why?
|
| Retrospective Studies | 1 | 2023 | 8495 | 0.090 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 492 | 0.090 |
Why?
|
| Diet | 1 | 2012 | 443 | 0.080 |
Why?
|
| Relaxation Therapy | 1 | 2008 | 4 | 0.080 |
Why?
|
| Beverages | 1 | 2008 | 17 | 0.080 |
Why?
|
| Capsules | 1 | 2008 | 38 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2019 | 3243 | 0.080 |
Why?
|
| Demography | 1 | 2009 | 177 | 0.080 |
Why?
|
| Fear | 2 | 2023 | 78 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2009 | 369 | 0.080 |
Why?
|
| Central Nervous System Depressants | 1 | 2009 | 45 | 0.080 |
Why?
|
| Pain Threshold | 1 | 2008 | 58 | 0.080 |
Why?
|
| Individuality | 1 | 2009 | 109 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2010 | 596 | 0.080 |
Why?
|
| Control Groups | 1 | 2008 | 15 | 0.080 |
Why?
|
| Animals | 3 | 2020 | 26590 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 6513 | 0.080 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2008 | 122 | 0.080 |
Why?
|
| Social Environment | 2 | 2010 | 188 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2011 | 575 | 0.080 |
Why?
|
| Models, Neurological | 1 | 2011 | 405 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2008 | 157 | 0.080 |
Why?
|
| Registries | 1 | 2011 | 703 | 0.080 |
Why?
|
| Child Psychiatry | 1 | 2007 | 9 | 0.080 |
Why?
|
| Prolactin | 2 | 2006 | 88 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 526 | 0.070 |
Why?
|
| Genetic Linkage | 1 | 2008 | 623 | 0.070 |
Why?
|
| Binding Sites | 1 | 2009 | 1098 | 0.070 |
Why?
|
| Drug Therapy | 1 | 2007 | 70 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2010 | 769 | 0.070 |
Why?
|
| Genome, Human | 1 | 2011 | 756 | 0.070 |
Why?
|
| Risk-Taking | 1 | 2007 | 148 | 0.070 |
Why?
|
| Rhode Island | 1 | 2005 | 9 | 0.070 |
Why?
|
| Genotype | 2 | 2010 | 1852 | 0.070 |
Why?
|
| Discriminant Analysis | 1 | 2005 | 66 | 0.070 |
Why?
|
| Alcohol-Related Disorders | 1 | 2005 | 17 | 0.070 |
Why?
|
| Subarachnoid Space | 1 | 2005 | 17 | 0.070 |
Why?
|
| Hormones | 1 | 2006 | 141 | 0.070 |
Why?
|
| Receptors, Serotonin | 1 | 2005 | 34 | 0.060 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2005 | 18 | 0.060 |
Why?
|
| Sexual Maturation | 1 | 2005 | 35 | 0.060 |
Why?
|
| Schizophrenia | 1 | 2008 | 464 | 0.060 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2005 | 57 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 1961 | 0.060 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2005 | 92 | 0.060 |
Why?
|
| Baltimore | 1 | 2004 | 36 | 0.060 |
Why?
|
| Anticonvulsants | 1 | 2005 | 126 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 329 | 0.060 |
Why?
|
| Radiography | 1 | 2005 | 811 | 0.060 |
Why?
|
| Behavior | 1 | 2003 | 85 | 0.060 |
Why?
|
| Patient Selection | 1 | 2006 | 686 | 0.050 |
Why?
|
| Patient Simulation | 1 | 2002 | 42 | 0.050 |
Why?
|
| Narcissism | 1 | 2020 | 4 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2004 | 376 | 0.040 |
Why?
|
| Pedigree | 2 | 2011 | 966 | 0.040 |
Why?
|
| Geriatrics | 1 | 1979 | 61 | 0.040 |
Why?
|
| Phenotype | 1 | 2005 | 2380 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2005 | 3613 | 0.040 |
Why?
|
| Education, Medical | 1 | 1979 | 234 | 0.030 |
Why?
|
| Multilevel Analysis | 1 | 2011 | 21 | 0.030 |
Why?
|
| Finland | 1 | 2010 | 29 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2010 | 2357 | 0.020 |
Why?
|
| Mice, 129 Strain | 1 | 2010 | 55 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2010 | 77 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 826 | 0.020 |
Why?
|
| Founder Effect | 1 | 2010 | 104 | 0.020 |
Why?
|
| Child Development | 1 | 2011 | 163 | 0.020 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2009 | 31 | 0.020 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2008 | 13 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2008 | 145 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 1001 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2009 | 294 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2008 | 677 | 0.020 |
Why?
|
| Cell Line | 1 | 2010 | 2469 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2010 | 1924 | 0.020 |
Why?
|
| Autistic Disorder | 1 | 2007 | 147 | 0.020 |
Why?
|
| Placebos | 1 | 2005 | 218 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1564 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 1921 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 2271 | 0.010 |
Why?
|
| Mutation | 1 | 2008 | 3968 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 11356 | 0.010 |
Why?
|
| Curriculum | 1 | 1979 | 543 | 0.010 |
Why?
|